Field Medical Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference

Field Medical announced that its founder, Steven Mickelsen, MD, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, in San Francisco. The presentation will provide a company overview and highlight progress across the FieldForce™ PFA platform, including ventricular tachycardia and atrial fibrillation programs.

Read the full press release here.

First-in-Human VCAS Trial Results with FieldForce™ Ablation System Published in Circulation

Results from the first-in-human Ventricular Catheter Ablation Study (VCAS) evaluating Field Medical’s FieldForce™ Ablation System have been published in Circulation. The peer-reviewed article reports six-month outcomes demonstrating 82% freedom from VT/VF recurrence or ICD therapy and a 98% reduction in ventricular arrhythmia burden, marking an important clinical milestone in pulsed field ablation for ventricular tachycardia.

Read the full press release here.

Circulation Publishes 6-Month Outcomes from First-in-Human VCAS Trial of FieldForce™ Pulsed Field Ablation System: 82% Freedom from VT/VF Recurrence and 98% Reduction in Burden

CARDIFF-BY-THE-SEA, Calif. and PHILADELPHIA, Oct. 10, 2025 /PRNewswire/ -- Field Medical, Inc. today announced that Circulation has published six-month outcomes from the Ventricular Catheter Ablation Study (VCAS), the first-in-human evaluation of its FieldForce™ Ablation System for ventricular tachycardia (VT). Results were also presented as a late-breaking trial at the 20th Annual International Symposium on Ventricular Arrhythmias (VT Symposium).

Read the full press release here.